Long‐Term Follow Up in Anti‐Contactin‐1 Autoimmune Nodopathy

Patients with anti-CNTN1<sup>+</sup> autoimmune nodopathy have a characteristic clinical profile. Clinical and immunological relapses are infrequent after successful treatment, suggesting that continuous treatment is unnecessary. Anti-CNTN1 antibodies, sNfL, and sCNTN1 levels are useful to monitor disease status in these patients. ANN NEUROL 2025;97:529-541.

Authors

Institutions

Publication Details

Journal
Annals of Neurology
Published
2024-11-27
DOI
https://doi.org/10.1002/ana.27142
Citations
11
Primary Topic
Peripheral Neuropathies and Disorders
Type
article
Field-Weighted Citation Impact
4.06

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Long‐Term Follow Up in Anti‐Contactin‐1 Autoimmune Nodopathy

Barbara Castek, Fu Liong Hiew, J Roche, Roger Collet‐Vidiella et al.
11 citations
Annals of Neurology
Peripheral Neuropathies and Disorders
4.06
article

Long‐Term Follow Up in Anti‐Contactin‐1 Autoimmune Nodopathy

Barbara Castek, Fu Liong Hiew, J Roche, Roger Collet‐Vidiella, Davide Sparasci, Luís Querol, Milou R. Michael, Elisa Vegezzi, Amaia Jauregui, Paolo Ripellino, Eduardo Nobile‐Orazio, Laura Martínez‐Martínez, Helena Pérez‐Pérez, Susanne Grinzinger, Luuk Wieske, Tomás Xuclà‐Ferrarons, Elba Pascual‐Goñi, Nicolau Ortiz, Kevin M. Rostasy, Émilien Delmont, Kai‐Nicolas Poppert, Julia Wanschitz, Cinta Lleixà, Eduard Gallardo, Adája E. Baars, Pietro Emiliano Doneddu, Stephan Iglseder, Romana Höftberger, Joep Killestein, Alejandro Horga, Thaís Armangué, Marta Caballero‐Ávila, Bart C. Jacobs, Luca Diamanti, Alicia Alonso‐Jiménez, Álvaro Carbayo, Clara Tejada‐Illa, Fabian Zach, Franscisco Javier Rodriguez de Rivera, Charlotte C.E. Teunissen, Elisabeth Lindeck Pozza, Filip Eftimov, Jonathan De Winter, Marleen J.A. Koel‐Simmelink, Maria Ángeles del Real, Amaia Gonzalez
article en
11 citations

Abstract

Patients with anti-CNTN1<sup>+</sup> autoimmune nodopathy have a characteristic clinical profile. Clinical and immunological relapses are infrequent after successful treatment, suggesting that continuous treatment is unnecessary. Anti-CNTN1 antibodies, sNfL, and sCNTN1 levels are useful to monitor disease status in these patients. ANN NEUROL 2025;97:529-541.

Annals of NeurologyVol. 97(3)
Universitat Autònoma de Barcelona (ES), Hospital Sant Joan de Déu Barcelona (ES), Humanitas University (IT), Innsbruck Medical University (AT), University of Antwerp (BE), Witten/Herdecke University (DE), Universität Innsbruck (AT), Hospital Universitario de Canarias (ES), Hospital Universitario La Paz (ES), Hospital de Sant Pau (ES), Erasmus MC (NL), Hospital Clínico San Carlos (ES), Landeskrankenhaus Feldkirch (AT), Antwerp University Hospital (BE), Christian Doppler Klinik (AT), Centre for Biomedical Network Research on Rare Diseases (ES), Hospital Universitario Miguel Servet (ES), Centro de Investigación Biomédica en Red (ES), Hospital General Universitario de Ciudad Real (ES), Hospital de Sant Joan Despí Moisès Broggi (ES), Hospital de Cruces (ES), Hospital Universitari Sant Joan de Reus (ES), Amsterdam University Medical Centers (NL), Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES), Hôpital de la Timone (FR), IRCCS Humanitas Research Hospital (IT), Università della Svizzera italiana (CH), Universidad Autónoma de Madrid (ES), Universitat de Barcelona (ES), Medical University of Vienna (AT), Sunway University (MY), University of Amsterdam (NL)
Instituto de Salud Carlos III
Good health and well-being
Openalex Percentile: Top 5%
Peripheral Neuropathies and Disorders
4.06
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.